We are live on
!
Find out more
JHC
Jones Hill Capital Portfolio holdings
AUM
$470M
This Fund
S&P 500
This Quarter
Est. Return
+12.68%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$466M
AUM Growth
–
Cap. Flow
+$455M
Cap. Flow
% of AUM
97.57%
Top 10 Holdings %
Top 10 Hldgs %
73.06%
Holding
26
New
26
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$74M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$50.6M |
| 3 |
Vaxcyte
PCVX
|
+$35M |
| 4 |
NUVL
Nuvalent
NUVL
|
+$30.7M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$26.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$10.6B
| $71.7M | 15.36% |
+1,268,390
| New | +$74M |
2026 Q1
0 quarters
|
|
|
2
Vertex Pharmaceuticals
VRTX
$128B
| $48.5M | 10.4% |
+108,603
| New | +$50.6M |
2026 Q1
0 quarters
|
|
|
3
Vaxcyte
PCVX
$9.68B
| $37.5M | 8.03% |
+644,831
| New | +$35M |
2026 Q1
0 quarters
|
|
|
NUVL
4
DELISTED
Nuvalent
NUVL
| $30.8M | 6.61% |
+300,830
| New | +$30.7M |
2026 Q1
0 quarters
|
|
5
Capricor Therapeutics
CAPR
$466M
| $27.6M | 5.93% |
+909,207
| New | +$24.2M |
2026 Q1
0 quarters
|
|
|
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
| $27.5M | 5.89% |
+521,237
| New | +$21.4M |
2026 Q1
0 quarters
|
|
|
BCAX
7
Bicara Therapeutics
BCAX
$1.14B
| $25.1M | 5.37% |
+1,260,136
| New | +$21.7M |
2026 Q1
0 quarters
|
|
8
ANI Pharmaceuticals
ANIP
$1.65B
| $24.5M | 5.25% |
+318,591
| New | +$24.9M |
2026 Q1
0 quarters
|
|
|
9
Ultragenyx Pharmaceutical
RARE
$1.51B
| $24.4M | 5.23% |
+1,165,557
| New | +$26.2M |
2026 Q1
0 quarters
|
|
10
Enliven Therapeutics
ELVN
$2.98B
| $23.2M | 4.98% |
+593,040
| New | +$16.4M |
2026 Q1
0 quarters
|
|
11
Amylyx Pharmaceuticals
AMLX
$3.41B
| $22.2M | 4.76% |
+1,598,794
| New | +$22.5M |
2026 Q1
0 quarters
|
|
12
argenx
ARGX
$51.5B
| $19M | 4.07% |
+25,995
| New | +$20.3M |
2026 Q1
0 quarters
|
|
13
Fulcrum Therapeutics
FULC
$286M
| $13.6M | 2.91% |
+1,771,926
| New | +$16.4M |
2026 Q1
0 quarters
|
|
14
Vir Biotechnology
VIR
$1.88B
| $10.7M | 2.3% |
+1,198,213
| New | +$9.55M |
2026 Q1
0 quarters
|
|
15
Nuvation Bio
NUVB
$1.74B
| $10.2M | 2.19% |
+2,383,031
| New | +$13.3M |
2026 Q1
0 quarters
|
|
|
ORKA
16
Oruka Therapeutics
ORKA
$5.12B
| $6.91M | 1.48% |
+140,843
| New | +$4.89M |
2026 Q1
0 quarters
|
|
|
CTNM
17
Contineum Therapeutics
CTNM
$496M
| $6.7M | 1.44% |
+513,053
| New | +$6.88M |
2026 Q1
0 quarters
|
|
|
MANE
18
Veradermics Inc
MANE
$5.29B
| $6.37M | 1.37% |
+100,843
| New | +$5.09M |
2026 Q1
0 quarters
|
|
19
Tonix Pharmaceuticals
TNXP
$125M
| $6.22M | 1.33% |
+452,116
| New | +$6.96M |
2026 Q1
0 quarters
|
|
20
Structure Therapeutics
GPCR
$1.83B
| $4.85M | 1.04% |
+100,593
| New | +$6.88M |
2026 Q1
0 quarters
|
|
21
Entrada Therapeutics
TRDA
$215M
| $4.72M | 1.01% |
+374,010
| New | +$4.29M |
2026 Q1
0 quarters
|
|
22
Pharvaris
PHVS
$2.18B
| $4.72M | 1.01% |
+167,014
| New | +$4.46M |
2026 Q1
0 quarters
|
|
23
Trevi Therapeutics
TRVI
$1.83B
| $4.42M | 0.95% |
+370,175
| New | +$4.14M |
2026 Q1
0 quarters
|
|
24
Relmada Therapeutics
RLMD
$338M
| $2.39M | 0.51% |
+342,752
| New | +$1.62M |
2026 Q1
0 quarters
|
|
|
SLN
25
Silence Therapeutics
SLN
$592M
| $1.59M | 0.34% |
+301,604
| New | +$1.66M |
2026 Q1
0 quarters
|
|
Similar funds
AIM
BFA
ACM
HNWAG
DBRC
DWML
CFLC
PWM
Jones Hill Capital's Q1 2026 Portfolio in Review
Q1 2026 is the first quarter with a 13F filing on record for Jones Hill Capital, which disclosed 26 positions worth $466M. Its ten largest holdings account for 73% of the portfolio.
Its largest position is BioMarin Pharmaceuticals: 1,268,390 shares worth $71.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Jones Hill Capital's largest Q1 2026 buy was BioMarin Pharmaceuticals: 1,268,390 shares worth $71.7M.
- Jones Hill Capital's ten largest holdings make up 73% of its $466M portfolio in Q1 2026.
- Jones Hill Capital disclosed 26 positions in Q1 2026, its first 13F filing on record.
Based on Jones Hill Capital's 13F filing for Q1 2026, filed 14 May 2026.